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Summary A restriction site-generating polymerase chain reaction (RG-PCR) assay was developed to detect the BRCAl 5382insC mutation
that has been reported in multiple, apparently unrelated breast/ovarian carcinoma families. The assay has been used to screen tumour DNA
from 250 breast cancer patients (aged 19-86 years) and from 80 ovarian cancer patients (aged 25-90 years) in a local population of patients
with no known family history. Altogether, 0/80 (0%) ovarian and 1/250 (0.4%) breast tumour DNAs were found to have the 5382insC mutation.
The sole positive case was a 26-year-old woman (BC185) with no known family history. One of the reasons for carrying out this analysis was
that the 5382insC mutation had previously been shown to segregate with the disease in a very large Scottish 'West Lothian' kindred having
breast/ovarian carcinoma. To investigate whether this apparently isolated case and the known family might be related, haplotypes for the
markers D17S855, D17S1322, D17S1323 and D17S1327 were analysed. The mutant haplotype in the large kindred was identical to that
reported in all other 5382insC mutation families for all markers with the exception of D17S1327. This implies that there has been a
recombination event at the telomeric end of common ancestral haplotype in this family. Since the isolated case we identified carries the
Icomplete' common haplotype, it is unlikely that she is closely related to the West Lothian family.
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The BRCAJ gene was first mapped to chromosome 17q by linkage
analysis (Hall et al, 1990; Narod et al, 1991) and subsequently by
positional cloning (Miki et al, 1994; Futreal et al, 1994). The gene
contains 22 coding exons distributed over more than 100 kb and
codes for a protein of 1863 amino acids. Loss-of-function muta-
tions in the BRCAJ gene on 17q21 are responsible for about half
of all familial early onset female breast cancers. Furthermore,
80-90% of families in which two or more cases of early onset
breast cancer and two or more cases ofovarian cancer occur carry
BRCAJ mutations (Easton et al, 1993; Narod et al, 1995). Such
genetic predispositions are thought to be responsible for between
5% and 10% of all females with breast cancer (Newman et al,
1988; Claus et al, 1991).
The BRCAJ 5382insC mutation has been widely reported
(Castilla et al, 1994; Friedman et al, 1994; Gayther et al, 1995),
including a study of four apparently unrelated Canadian families
(Simard et al, 1994). Each of these families shared a common
haplotype around the BRCAJ gene and are thus thought to be of
the same ancestral mutation. This mutation was recently identified
in a large Scottish 'West Lothian' family with familial breast/
ovarian carcinoma (manuscript in preparation), suggesting that
Scottish families may share the same ancestral chromosome seen
in the aforementioned Canadian families.
The present study was carried out in order to develop a robust
restriction site-generating polymerase chain reaction (RG-PCR)-
based assay for 5382insC to enable us to determine the incidence
ofthis mutation in a group of Scottish sporadic breast and ovarian
cancer patients routinely presenting for surgery.
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MATERIALS AND METHODS
Subjects
Two hundred tumour samples were obtained from women under-
going either biopsy, lumpectomy or mastectomy for histologically
confirmed primary breast cancer. Tumours were randomly
selected on the basis of sample availability from a tumour bank
commencing with the most recent eligible patient (a minimum
sample size for extraction of 100 mg was chosen). Although these
samples were anonymized, information on the age atdiagnosis and
the presence of a family history (first-degree relative with breast or
ovarian cancer) was retained on each sample. A separate cohort of
50 women was selected on the basis that they had presented with
primary breast cancer by the age of 40 years. Tumours were
obtained from women presenting with histologically proven breast
cancer in the Edinburgh area between February 1988 and
December 1995, all samples having been stored in liquid nitrogen.
In addition, 80 ovarian tumours that had again been made avail-
able through various hospitals in the Edinburgh area were
extracted. Similarly, none of these patients were known to have a
family history ofovarian cancer.
DNA extraction from tumours
Extraction of DNA was performed essentially as described in the
Nucleon II kit (Scotlab, UK) manual. The 330 tumours were
removed from liquid nitrogen, weighed, chopped into small pieces
using sterile scissors and transferred into a flat-bottomed glass
homogenization tube. Cross-contamination between serially
extracted samples was eliminated by washing the homogenizer in
tap water (x 2), 10% neutracon (x 1), 5% neutracon (x 1), 1%
neutracon (x 1), distilled water (x 1), ethanol (x 1) and fresh buffer
between each extraction. Between 100 mg and 500 mg wet weight
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of tissue was extracted using 800 1t of silica suspension for each
sample. At the end ofthe extraction procedure, DNA was precipi-
tated with ethanol, spooled, air dried and resuspended in TE. For
each tumour, a stock DNA solution at 200 ng 1d-' was prepared for
PCR analysis.
PCR design
The mutation 5382insC is found towards the 3'-end of exon 20 in
the BRCAJ gene. The C at position 5383 in exon 20 ofthe BRCAJ
is part of a natural BstOl site, CC(A/T)GG. Mismatching of the
penultimate base of the 5' primer results in the elimination ofthis
site. The 5382insC mutation restores the site in the PCR product
(see below and Figure).
Wt sequence GAA TC(C CAG Wt BstOl site in
Mutant
sequence
Primer 5'
terminus
Wt RG-PCR
product
5382insC
RG-PCR
product (ins
G)AC
GAA TCC CCA
GGA C
GAA TCTC
GAA TCT CAG GAC
GAA TCT (CCA
GG)A C
brackets
Inserted base at
5382 underlined
Mismatched base
underlined
Site absent in PCR
product
Restored site in
brackets
serted base at 5382 underlined and bold)
5382insC RG-PCR assay
PCR amplifications were performed using 50-il reaction volumes.
The following buffer components were found to give optimal
amplification: 1.5 mm magnesium chloride, 10 mm Tris-HCl,
pH 8.3, 50 mm potassium chloride, 200 [tM dATP, 200 FtM dCTP
200 jiM dGGTP and 200 jiM dTTP. Genomic DNA (200 ng; 1 jil)
and approximately 1 jtl of Taq polymerase (Cetus) were used for
each reaction. The 5' exon 20 primer CAA GGT CCA AAG CGA
GCA AGA GAA TCT C (0.5 jtM) and the 3' flanking primer
AAATGGCCT(CCA GGG) AAT CCA AAT TAC ACA GC (0.5
AtM) were used. Samples were overlaid with mineral oil and incu-
bated for
4 min at 94°C before the addition ofthe Taq polymerase. The reac-
tions were subjected to 30 cycles of 94°C for 1 min, 58°C for
1 min and 72°C for 1 min followed by a 10-min extension at72°C.
PCR products were digested overnight with the restriction enzyme
BstO1 and resolved on a 2% ethidium bromide-stained agarose gel
run in 0.5 x TBE.
Table Age range of 250 breast cancer and 80 ovarian cancer patients
Age bands Breast Breast Ovarian
(years) BC001-BC200 BC201-BC250 OC001-OC080
<30 6 7 2
31-40 11 43 2
41-50 72 16
51-60 58 25
61-70 44 16
>70 9 19
293 bp 28
2 bp +_i
255 bp _II
1 2 3 4 5 6 7 8
Figure Ethidium-stained 2% agarose gel of the RG-PCR assay for 5382insC
mutation. Lane 1 is the DNA-negative control; lanes 2 and 8 are undigested
PCR products of 293 bp; lanes 4, 5 and 7 are breast tumour DNAs without
the 5382insC mutation digested with BstOl giving a band of 282 bp; lane 3
is the BstOl-digested PCR product from an affected member of the West
Lothian kinship giving 282-bp (normal) and 255-bp (mutant allele) bands;
lane 6 shows a BstOl-digested PCR product from individual BC185 (showing
an identical pattern to lane 3)
Fluorescent PCR
The microsatellite markers, D17S855 (Weissenbach et al, 1992),
D17S1322, D17S1323 (Neuhausen et al, 1995) and D17S1327
(Goldgar et al, 1994), were used in this study. Analysis using an
automatic laser fluorescent sequencer was essentially as described
previously (Warner et al, 1996). Allele sizes were determined by
reference to fluorescently labelled fragments of known size and
by reference to amplification products from a patient typed in
another laboratory in which allele sizes were determined by
DNA sequencing.
RESULTS
Age distribution of patients
The age profile of (1) the initial 200 breast cancer patients
(BCOOI-BC200); (2) the 50 breast cancer patients presenting by
the age of 40 years(BC201-BC250); and (3) the 80 patients with
ovarian tumours are (OCOO1-OC080) shown in the Table.
BRCA1 5382insC mutation analysis
Of the 200 sporadic breast tumour DNAs initially tested, one was
found to have a BRCAJ 5382insC mutation. Since samples had
been anonymized following DNA extraction and the age of the
individual concerned had been incorporated into a coded sample
number, this could be determined. Coded DNA samples, along
with the destruction of lists showing the exact composition of
patient cohorts, prevented retrospective identification of any indi-
vidual patient. Code analysis ofsample BC185 showed the woman
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to be 26 years of age. No further mutations were detected in the
cohort of 50 breast cancer patients aged 40 years or less that were
subsequently analysed. This represents a total frequency of 1/250
(0.5%) for all breast cancer patients tested (1.31% of the 76
patients aged 40 years or less, or 7.7% of the 13 patients aged 30
years or less). Of the ovarian DNA samples analysed, 0/80 (0%)
were found to contain the BRCAJ 5382insC mutation.
The RG-PCR result for the positive breast cancer sample
(BC185), along with appropriate negative and positive control
samples, is shown in the Figure. The single-strand conformational
polymorphis (SSCP) band patterns observed for this sample were
identical to those seen in the positive sample from the West
Lothian 5382insC kindred, but different from those observed in
normal individuals (data not shown).
Haplotype analysis
Haplotype analysis of the single sample found to be positive for
the 5382insC mutation was performed using the markers
D17S855, D17S1322, D17S1323 and D17S1327. Using the
convention for describing allele sizes established by Simard et al
(1994), our positive sample had the haplotype D/A for D17S855,
E/E for D17S1322, F/F for D17S1323 and O/M for D17S1327.
Haplotyping carried out with five affected members of the West
Lothian kindred along with BC185 revealed a 2-bp difference
between BC185 (DEFO) and all five kindred members (DEFN).
Since the haplotype commonly found with the 5382insC mutation
is DEFO, the genotype for ourpositive sample would be consistent
with this.
DISCUSSION
The initial hypothesis that 'given the existence of a very large
kindred with the BRCAJ 5382insC mutation in the West Lothian
region, the incidence of this mutation might be considerably
higher for women with breast cancer within a Scottish population'
was shown to be unfounded. However, the identification of the
5382insC mutation in a 26-year-old woman from our cohort of
patients with breast cancer highlights a low, but significant, inci-
dence of the BRCAJ 5382insC mutation. Indeed, we believe this
represents the only reported incidence of the mutation in a
sporadic population ofbreast cancer patients. While only 13 breast
cancer patients aged 30 years or less were available for study, the
single sample having the mutation in question was shown to
belong to this group (representing a mutation frequency of almost
8% within this subpopulation).
Haplotyping of the sporadic breast cancer, BC185, along with
members of the Scottish West Lothian kinship, revealed the pres-
ence of a single telomeric difference in the haplotype commonly
associated with the 5382insC mutation in the West Lothian
kinship. Interestingly, it is the West Lothian kindred that is
unusual, since the haplotype associated with the 5382insC muta-
tion differs at the marker D17S1327, being 2 bp larger (DEFN)
than the common haplotype (DEFO) reported previously. Despite
this unexpected finding, particularly in view ofthe common haplo-
type found in the sporadic case BC185, this observation has been
reported previously by Gayther et al (1995) (family B082), and
this was subsequently confirmed for this study. This recombina-
tion strengthens the suggestion that this mutant chromosome is a
relatively old mutation.
In conclusion, these results suggest that the Scottish mutant
haplotypes, although not identical, are likely to be derived from
the same ancestral chromosome as those found in Canada.
Furthermore, we believe that all Scottish women from suspected
breast cancer families should be screened for the mutation
5382insC, particularly in the light of the frequency detection rate
found in this population ofsporadic breast cancers.
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